Novartis investigative site
Newark, New Jersey 07112
0 studies enrolling now · 12 studies all time
What they study most
Acute Decompensated Heart Failure, Acute Heart Failure, Complicated Urinary Tract Infections, Congestive Heart Failure, Cytokine Storm (Covid-19), Heart Failure With Reduced Ejection Fraction, Hepatitis C, Liver Transplant Recipient, Liver Transplantation, Major Depressive Disorder, Neoplasms, Breast, Pulmonary Arterial Hypertension
Studies at this site
- Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm — Completed
- Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode. — Completed
- Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder — Completed
- MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone — Stopped early
- Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients — Completed
- LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI) — Withdrawn before enrolling
- Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants — Completed
- This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
- EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer — APPROVED_FOR_MARKETING
- Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension — Completed
- Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure — Completed
- Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients — Completed